Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LERFOX-C: Cetuximab with Oxaliplatin, 5-FU, and Radiotherapy in Esophageal Cancer
NCT02636088Phase 2Unknown
- Start
- Jan 2011
- Primary completion
- Dec 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of cetuximab in esophageal cancer, gastric cardia cancer (GEJ). Status: unknown.
02
Drugs
cetuximab
03
Conditions
esophageal cancergastric cardia cancer (GEJ)
Beyond the preview
Go deeper on NCT02636088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02636088.